
Aprecia Pharmaceuticals: Innovating precision drug delivery systems for the US market.
Founded with a mission to revolutionize drug delivery systems, Aprecia Pharmaceuticals focuses on developing and manufacturing precision drug delivery products. The company leverages its proprietary 3D printing technology, ZipDose, which allows for the creation of rapidly disintegrating tablets that enhance patient compliance and therapeutic efficacy. Aprecia primarily serves the U.S. market, aiming to maximize the potential of pharmaceutical products through innovative formulation techniques.
Aprecia's notable affiliations include partnerships with leading pharmaceutical companies and investments from prominent healthcare investors. Key achievements include the successful commercialization of the first FDA-approved 3D-printed drug, Spritam, which treats epilepsy. The company's impact is significant in advancing pharmaceutical manufacturing technology, setting new standards for precision and patient-centric drug delivery solutions.

Amphastar Pharmaceuticals
amphastar.com

Aquestive Therapeutics
aquestive.com

Ezra Innovations
ezrapharma.com

ImprimisRx
imprimisrx.com

Liquidia
liquidia.com

Catalent
catalent.com

Tris Pharma
trispharma.com

Manhattan Pharmaceuticals

Impel Pharmaceuticals
impelpharma.com

Accu-Break Pharmaceuticals
accubreak.com

Acadia Pharmaceuticals
acadia-pharm.com

US Specialty Formulations

NovaDel Pharma

APT Pharmaceuticals

Concours Pharmaceuticals
Companies similar to Aprecia Pharmaceuticals include Amphastar Pharmaceuticals, Aquestive Therapeutics, Ezra Innovations and ImprimisRx.
Aprecia Pharmaceuticals was founded in 2003.
Aprecia Pharmaceuticals' headquarters is located in Langhorne, PA, US.
Aprecia Pharmaceuticals' most recent funding round was for $30M (USD) in July 2016.
As of Jul 5, 2016, Aprecia Pharmaceuticals has raised a total of $158.4M (USD).
Aprecia Pharmaceuticals has 80 employees as of Feb 5, 2024.